Glenmark Pharmaceuticals Limited — Important, 28-03-2025: General Updates

Glenmark Pharmaceuticals' wholly-owned subsidiary, IGI Inc., has announced plans to cease CMC development and clinical supplies manufacturing at its facility in La Chaux-de-Fonds, Switzerland, effective July 31, 2025. The facility has generated no turnover as its output was for internal consumption, with a net worth of ₹22.35 Cr. This strategic move aims to streamline operations by shifting manufacturing to established Contract Development and Manufacturing Organizations, aligning with the company's anticipated growth in clinical programs. Investors may view this as a positive outlook, reflecting a focus on operational efficiency and potential future growth.